Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3– TransCon CNP ...

A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a midstage study. Subjects taking Amgen's MariTide lost 20% of their body weight ...

Good day, and thank you for standing by. Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that today's conference is being ...

Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

Thermo Fisher has launched a suite of expanded CRO and CDMO services under its own brand, Accelerator™ Drug Development, intended to serve biotechs and pharmas.

Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question ...

Korro Bio, Inc. ( (KRRO) ) has released its Q3 earnings. Here is a breakdown of the information Korro Bio, Inc. presented to its investors.

The federal government is hoping a temporary break on GST will address a 'vibecession' that has gripped Canadians, Finance ...